<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Linezolid versus vancomycin for skin and soft tissue infections - Yue, J - 2016 | Cochrane Library</title> <meta content="Linezolid versus vancomycin for skin and soft tissue infections - Yue, J - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008056.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Linezolid versus vancomycin for skin and soft tissue infections - Yue, J - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008056.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008056.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Linezolid versus vancomycin for skin and soft tissue infections" name="citation_title"/> <meta content="Jirong Yue" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Bi Rong Dong" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="birongdong@163.com" name="citation_author_email"/> <meta content="Ming Yang" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Xiaomei Chen" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Taixiang Wu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Guan J Liu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD008056.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/01/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008056.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008056.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008056.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Bacterial Agents [adverse effects, *therapeutic use]; Drug Eruptions [etiology]; Length of Stay; Linezolid [adverse effects, *therapeutic use]; Pruritus [chemically induced]; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial [*drug therapy]; Soft Tissue Infections [*drug therapy]; Thrombocytopenia [chemically induced]; Vancomycin [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008056.pub3&amp;doi=10.1002/14651858.CD008056.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="23LRTUA6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008056\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008056\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008056.pub3",title:"Linezolid versus vancomycin for skin and soft tissue infections",firstPublishedDate:"Jan 7, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Wounds Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008056.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008056.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008056.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008056.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008056.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008056.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008056.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008056.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008056.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008056.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>20339 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008056.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#CD008056-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#CD008056-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#CD008056-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#CD008056-sec-0030"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#CD008056-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#CD008056-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#CD008056-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/appendices#CD008056-sec-0111"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/table_n/CD008056StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/table_n/CD008056StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Linezolid versus vancomycin for skin and soft tissue infections</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information#CD008056-cr-0002">Jirong Yue</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information#CD008056-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Bi Rong Dong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information#CD008056-cr-0004">Ming Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information#CD008056-cr-0005">Xiaomei Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information#CD008056-cr-0006">Taixiang Wu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information#CD008056-cr-0007">Guan J Liu</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information/en#CD008056-sec-0142">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 January 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008056.pub3">https://doi.org/10.1002/14651858.CD008056.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008056-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008056-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008056-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008056-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008056-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008056-abs-0001" lang="en"> <section id="CD008056-sec-0001"> <h3 class="title" id="CD008056-sec-0001">Background</h3> <p>The morbidity and treatment costs associated with skin and soft tissue infections (SSTIs) are high. Linezolid and vancomycin are antibiotics that are commonly used in treating skin and soft‐tissue infections, specifically those infections due to methicillin‐resistant <i>Staphylococcus aureus (</i>MRSA). </p> </section> <section id="CD008056-sec-0002"> <h3 class="title" id="CD008056-sec-0002">Objectives</h3> <p>To compare the effects and safety of linezolid and vancomycin for treating people with SSTIs. </p> </section> <section id="CD008056-sec-0003"> <h3 class="title" id="CD008056-sec-0003">Search methods</h3> <p>For this first update of this review we conducted searches of the following databases: Cochrane Wounds Group Specialised Register (searched 24 March 2015; The Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>); Ovid MEDLINE; Ovid MEDLINE (In‐Process &amp; Other Non‐Indexed Citations); Ovid EMBASE; and EBSCO CINAHL. We also contacted manufacturers for details of unpublished and ongoing trials. We scrutinised citations within all obtained trials and major review articles to identify any additional trials. </p> </section> <section id="CD008056-sec-0004"> <h3 class="title" id="CD008056-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) comparing linezolid with vancomycin in the treatment of SSTIs. </p> </section> <section id="CD008056-sec-0005"> <h3 class="title" id="CD008056-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials, assessed risk of bias and extracted data. The primary outcomes were clinical cure, microbiological cure, and SSTI‐related and treatment‐related mortality. We performed subgroup analyses according to age, and whether the infection was due to MRSA. </p> </section> <section id="CD008056-sec-0006"> <h3 class="title" id="CD008056-sec-0006">Main results</h3> <p>No new trials were identified for this first update. We included nine RCTs (3144 participants). Linezolid was associated with a significantly better clinical (RR 1.09, 95% CI 1.03 to 1.16) and microbiological cure rate in adults (RR 1.08, 95% CI 1.01 to 1.16). For those infections due to MRSA, linezolid was significantly more effective than vancomycin in clinical (RR 1.09, 95% CI 1.03 to 1.17) and microbiological cure rates (RR 1.17, 95% CI 1.04 to 1.32). No RCT reported SSTI‐related and treatment‐related mortality. There was no significant difference in all‐cause mortality between linezolid and vancomycin (RR 1.44, 95% CI 0.75 to 2.80). There were fewer incidents of red man syndrome (RR 0.04, 95% CI 0.01 to 0.29), pruritus (RR 0.36, 95% CI 0.17 to 0.75) and rash (RR 0.27, 95% CI 0.12 to 0.58) in the linezolid group compared with vancomycin, however, more people reported thrombocytopenia (RR 13.06, 95% CI 1.72 to 99.22), and nausea (RR 2.45, 95% CI 1.52 to 3.94) when treated with linezolid. It seems, from the available data, that length of stay in hospital was shorter for those in the linezolid group than the vancomycin group. The daily cost of outpatient therapy was less with oral linezolid than with intravenous vancomycin. Although inpatient treatment with linezolid cost more than inpatient treatment with vancomycin per day, the median length of hospital stay was three days shorter with linezolid. Thus, total hospital charges per patient were less with linezolid treatment than with vancomycin treatment. </p> </section> <section id="CD008056-sec-0007"> <h3 class="title" id="CD008056-sec-0007">Authors' conclusions</h3> <p>Linezolid seems to be more effective than vancomycin for treating people with SSTIs, including SSTIs caused by MRSA. The available evidence is at high risk of bias and is based on studies that were supported by the pharmaceutical company that makes linezolid. Further well‐designed, independently‐funded, RCTs are needed to confirm the available evidence. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008056-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008056-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008056-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008056-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008056-abs-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008056-abs-0004">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008056-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008056-abs-0002" lang="en"> <h3>Antibiotic drugs for treating skin and soft tissue infections</h3> <p>Skin and soft tissue infections such as impetigo, abscesses, ulcers, and surgical site infections are common infections of the skin. For serious skin and soft tissue infections involving the deeper tissues, the death rate and treatment costs are high. Linezolid and vancomycin are antibiotics that are effective in treating skin and soft tissue infections, particularly infections caused by bacteria that have developed resistance to some antibiotics. This review identified nine RCTs, with a total of 3144 participants, and compared treatment with linezolid against treatment with vancomycin for skin and soft tissue infections. No new trials were identified for this first update. Linezolid was found to be more effective than vancomycin for treating these infections. There were fewer skin complications in the group that were treated with linezolid. There were no differences between the two groups in the number of reported deaths, and those treated with linezolid had shorter lengths of hospital stay than those treated with vancomycin. The daily cost of outpatient therapy was less with oral linezolid than with intravenous vancomycin, although for inpatient treatment, linezolid was more expensive than vancomycin. Well‐designed trials will be required in future to confirm these results, as the trials from which these conclusions were drawn were of poor methodological quality, at high risk of bias, and were funded by the pharmaceutical company that makes linezolid. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008056-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008056-sec-0106"></div> <h3 class="title" id="CD008056-sec-0107">Implications for practice</h3> <section id="CD008056-sec-0107"> <p>The poor quality evidence contained within this systematic review shows that linezolid seems to be more effective than vancomycin for the treatment of patients with SSTIs and SSTIs caused by MRSA. The lengths of stay in hospital were shorter, and the costs of treatment were lower, for people in the linezolid group compared to the vancomycin group. Fewer people in the linezolid group suffered from red man syndrome, pruritus and rash compared with vancomycin, but more people in the linezolid group suffered from thrombocytopenia and nausea. In spite of these results, the evidence may be limited by potential biases, so further evidence from higher quality trials is necessary before definite conclusions can be drawn. </p> </section> <h3 class="title" id="CD008056-sec-0108">Implications for research</h3> <section id="CD008056-sec-0108"> <p>Further well‐designed and reported randomised controlled trials are needed to confirm the available evidence. The following features should be addressed in future studies: </p> <p> <ol id="CD008056-list-0009"> <li> <p>Detailed reporting of the methods of randomisation and allocation concealment.</p> </li> <li> <p>Application and clear description of blinding.</p> </li> <li> <p>Adverse events critically assessed by standardised reporting and RCTs with larger samples. </p> </li> <li> <p>Appropriate outcomes: mortality, cure rate, duration of hospital stay, duration of treatment, and cost‐effectiveness of the treatment. </p> </li> <li> <p>Pharmaceutical companies producing the drugs being assessed should not fund these trials. </p> </li> <li> <p>Reporting of the methods and results of the trials using relevant reporting standards.</p> </li> </ol> </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008056-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008056-sec-0022"></div> <p>Please see the Glossary of terms in <a href="./appendices#CD008056-sec-0112">Appendix 1</a> for additional information and definitions. </p> <section id="CD008056-sec-0023"> <h3 class="title" id="CD008056-sec-0023">Description of the condition</h3> <p>Skin and soft tissue infections (SSTIs) are common infections of the epidermis, dermis, or subcutaneous tissue and characterised by induration (hardening), erythema (redness), warmth and pain or tenderness and range from mild, self‐limiting furunculosis (boils) to life‐threatening necrotising fasciitis (<a href="./references#CD008056-bbs2-0054" title="StevensDL , BisnoAL , ChambersHF , EverettED , DellingerP , GoldsteinEJ , et al. Practice guidelines for the diagnosis and management of skin and soft‐tissue infections. Clinical Infectious Diseases2005;41(10):1373‐406. ">Stevens 2005</a>). SSTIs include: </p> <p> <ul id="CD008056-list-0001"> <li> <p>Impetigo.</p> </li> <li> <p>Abscesses, cellulitis (infection just under the skin), and erysipelas (skin infection).</p> </li> <li> <p>Necrotising skin and soft‐tissue infections.</p> </li> <li> <p>Infections following animal and human bites.</p> </li> <li> <p>Soft‐tissue infections following animal contact.</p> </li> <li> <p>Surgical site infections.</p> </li> <li> <p>Infections in people whose immune systems are compromised.</p> </li> <li> <p>Infections resulting from treatment (i.e. iatrogenic) (e.g. postoperative wounds).</p> </li> </ul> </p> <p>The Food and Drugs Administration (FDA) classifies SSTIs as either "uncomplicated" or "complicated". Uncomplicated SSTIs are superficial infections and simple surgical incisions amenable to treatment with antibiotics, e.g. simple abscesses, carbuncles, impetigo lesions, furuncles (boils), and cellulitis. Complicated SSTIs are infections involving the deeper tissues, such as subcutaneous tissue, fascia, and skeletal muscle, or SSTIs in patients with co‐morbidities such as diabetes mellitus, HIV, and other immunocompromised states (<a href="./references#CD008056-bbs2-0034" title="FDA . Uncomplicated and complicated skin and skin structure infections‐‐developing antimicrobial drugs for treatment. Guidance for Industry: Center for Drug Evaluation and Research (CDER). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf1998. ">FDA 1998</a>). SSTIs are caused by a wide variety of organisms, most of which are Gram‐positive (i.e. are stained by a particular biological dye). The SENTRY Antimicrobial Surveillance Program has been monitoring SSTIs in more than 70 medical centres in North America, Europe, Latin America, and the Asia‐Pacific region since 1997. Their report, which presents data over a seven year period (1998 to 2004), ranks SSTIs by frequency of pathogen as follows: <i>Staphylococcus aureus</i> , <i>Pseudomonas aeruginosa</i> , <i>Escherichia coli</i> , <i>Enterococcus</i> species, <i>Klebsiella</i> species, <i>Enterobacter</i> species, β‐haemolytic streptococci, coagulase‐negative staphylococci, <i>Proteus mirabilis</i> , and <i>Acinetobacter</i> species (<a href="./references#CD008056-bbs2-0036" title="FritscheTR , SaderHS , JonesRN . Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999‐2004). Diagnostic Microbiology and Infectious Disease2007;58(1):19‐26. ">Fritsche 2007</a>). The complications of SSTIs, particularly those caused by <i>Staphylococcus aureus</i>, may cause bacteraemia (bacteria in the blood) and induce focal points of infection, such as bacterial endocarditis (the lining of the heart), osteomyelitis (bones), brain abscesses, brain meningitis, and/or lung abscesses (<a href="./references#CD008056-bbs2-0030" title="EisensteinBI . Treatment challenges in the management of complicated skin and soft‐tissue infections. Clinical Microbiology and Infection2008;14(Suppl 2):17‐25. ">Eisenstein 2008</a>), at a distance from the original infection. </p> <p>The morbidity and treatment costs associated with SSTIs are high, and treatment has become more complex recently due to the increasing prevalence of multidrug‐resistant pathogens (<a href="./references#CD008056-bbs2-0048" title="MoetGJ , JonesRN , BiedenbachDJ , StilwellMG , FritscheTR . Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998‐2004). Diagnostic Microbiology and Infectious Disease2007;57(1):7‐13. ">Moet 2006</a>). During the past decade the prevalence of antibiotic resistance among Gram‐positive cocci (bacteria) ‐ particularly <i>Staphylococcus aureus ‐</i> has increased sharply. A considerable variation in the methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA) rate was noted between countries and continents. According to the SENTRY report, the MRSA infection rate of all infections was 35.9 per cent in North America, compared with 29.4 per cent in Latin America and 22.8 per cent in Europe. The MRSA rate of all infections varied considerably among the European countries too, ranging from 0.8 per cent in Sweden to 50 per cent in Portugal (<a href="./references#CD008056-bbs2-0036" title="FritscheTR , SaderHS , JonesRN . Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999‐2004). Diagnostic Microbiology and Infectious Disease2007;58(1):19‐26. ">Fritsche 2007</a>). Variability in MRSA infection rate was also apparent in Latin America, where Mexico had 50 per cent of all infections, Chile 38 per cent, Brazil 29 per cent, Argentina 28 per cent, and Columbia and Venezuela combined had 3 per cent (<a href="./references#CD008056-bbs2-0048" title="MoetGJ , JonesRN , BiedenbachDJ , StilwellMG , FritscheTR . Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998‐2004). Diagnostic Microbiology and Infectious Disease2007;57(1):7‐13. ">Moet 2006</a>). Antibiotic resistance increases the length of stay in hospital, costs of treatment and the mortality rate. A review of the epidemiology of severe <i>Staphylococcus aureus</i> infections in Europe reports that the overall seven‐day case fatality rate was 19 per cent (<a href="./references#CD008056-bbs2-0044" title="LamagniTL , DarenbergJ , Luca‐HarariB , SiljanderT , EfstratiouA , Henriques‐NormarkB , et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. Journal of Clinical Microbiology2008;46(7):2359‐67. ">Lamagni 2008</a>). A US study reported that patients with MRSA‐infected surgical sites had a three times greater 90‐day mortality rate and a greater duration of hospitalisation after infection (median additional days 5; P value less than 0.001) than patients infected by methicillin‐sensitive<i>Staphylococcus aureus</i> (MSSA). Median hospital charges were USD 92,363 for patients with MRSA surgical site infections compared with USD 52,791 for patients with MSSA infections (<a href="./references#CD008056-bbs2-0031" title="EngemannJJ , CarmeliY , CosgroveSE , FowlerVG , BronsteinMZ , TrivetteSL , et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clinical Infectious Diseases2003;36(5):592‐8. ">Engemann 2003</a>). </p> </section> <section id="CD008056-sec-0024"> <h3 class="title" id="CD008056-sec-0024">Description of the intervention</h3> <p>The treatment of uncomplicated SSTIs and complicated SSTIs differs, with different clinical outcomes. Uncomplicated SSTIs are usually treated locally with, or without, antibiotics, whereas most complicated SSTIs require hospitalisation, treatment with intravenous antibiotics, and possibly surgical intervention (<a href="./references#CD008056-bbs2-0032" title="EronLJ , LipskyBA , LowDE , NathwaniD , TiceAD , VolturoGA . Managing skin and soft tissue infections: expert panel recommendations on key decision points. Journal of Antimicrobial Chemotherapy2003;52(Suppl 1):i3‐i17. ">Eron 2003</a>). Choice of the initial antibiotic is crucial for patients with complicated SSTIs. It has been demonstrated that correct use of antibiotics is associated with lower morbidity and mortality in patients who have an infection (<a href="./references#CD008056-bbs2-0025" title="BouzaE , SousaD , MuñozP , Rodríguez‐CréixemsM , FronC , LechuzJG . Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Journal of Infectious Diseases2004;39(8):1161‐9. ">Bouza 2004</a>). </p> <p>The antibiotics commonly used for the treatment of SSTIs caused by Gram‐positive cocci are beta‐lactams (including semisynthetic penicillins and cephalosporins), clindamycin, vancomycin, and linezolid (<a href="./references#CD008056-bbs2-0038" title="FungHB , ChangJY , KuczynskiS . A practical guide to the treatment of complicated skin and soft tissue infections. Drugs2003;63(14):1459‐80. ">Fung 2003</a>). Beta‐lactam antibiotics remain the mainstay of treatment for suspected streptococcal and MMSA infections. In proven penicillin‐sensitive infection, use of benzyl penicillin remains appropriate. Clindamycin can be administered in combination with beta‐lactam antibiotics for rapidly‐progressing infections, such as severe streptococcal infections, where beta‐lactam antibiotics alone are less effective. During the past decade the prevalence of antibiotic resistance among Gram‐positive cocci (e.g. MRSA) has increased sharply. Vancomycin has been the mainstay of therapy in MRSA infections and for patients who are intolerant of or allergic to the beta‐lactams. Linezolid is a novel oxazolidinone agent for use against staphylococci and enterococci, with a spectrum of activity against Gram‐positive bacteria similar to that of vancomycin so linezolid and vancomycin are often compared. </p> </section> <section id="CD008056-sec-0025"> <h3 class="title" id="CD008056-sec-0025">How the intervention might work</h3> <section id="CD008056-sec-0026"> <h4 class="title">Mechanism of action</h4> <p>Vancomycin is a traditional antibiotic for the treatment of Gram‐positive cocci, especially MRSA, which acts by inhibiting proper cell wall synthesis in Gram‐positive bacteria. Due to the different mechanism by which Gram‐negative bacteria produce their cell walls, and the various factors related to entering the outer membrane of Gram‐negative organisms, vancomycin is not active against Gram‐negative bacteria (except some non‐gonococcal species of <i>Neisseria</i>). </p> <p>Linezolid, the first member of the oxazolidinone class of antibiotics to be approved by the FDA, is indicated for the treatment of SSTIs caused by methicillin‐sensitive or methicillin‐resistant <i>S aureus,</i> or vancomycin‐resistant enterococci and other susceptible micro‐organisms (<a href="./references#CD008056-bbs2-0037" title="FungHB , KirschenbaumHL , OjofeitimiBO . Linezolid: an oxazolidinone antimicrobial agent. Clinical Therapeutics2001;23(3):356‐91. ">Fung 2001</a>). Linezolid has a unique mechanism of action. It stops the growth and reproduction of bacteria by disrupting translation of messenger RNA into proteins in the ribosome. Linezolid selectively binds to the 50S ribosomal unit and inhibits initiation of complex protein synthesis (<a href="./references#CD008056-bbs2-0056" title="WilsonDN , SchluenzenF , HarmsJM , StarostaAL , ConnellSR , FuciniP . The oxazolidinone antibiotics perturb the ribosomal peptidyl‐transferase center and effect tRNA positioning. Proceedings of the National Academy of Sciences2008;105(36):13339. ">Wilson 2008</a>). This unique mechanism has not been seen in any other antibiotic agents, thus, cross‐resistance of linezolid has not been observed. One of the advantages of linezolid is its high bioavailability when given by mouth (close to 100 per cent). This means that people receiving intravenous linezolid may be switched to oral linezolid as soon as their condition allows it, whereas vancomycin can only be given intravenously (<a href="./references#CD008056-bbs2-0047" title="MoelleringRCJr . A novel antimicrobial agent joins the battle against resistant bacteria. Annals of Internal Medicine1999;130(2):155‐7. ">Moellering 1999</a>). </p> </section> <section id="CD008056-sec-0027"> <h4 class="title">Resistance</h4> <p>During recent years, the decreasing susceptibility of some bacteria to traditional antibiotics has been a significant problem in treating SSTIs. The increasing incidence of infections caused by resistant Gram‐positive cocci has led to a sharp increase in the use of vancomycin (<a href="./references#CD008056-bbs2-0049" title="PallaresR , DickR , WenzelRP , AdamsJR , NettlemanMD . Trends in antimicrobial utilization at a tertiary teaching hospital during a15‐year period (1978–1992).  Infection Control and Hospital Epidemiology1993;14(7):376–82. ">Pallares 1993</a>). As a result, the emergence of vancomycin‐resistant strains of enterococci and staphylococci has been widely observed in the last few years. Between the years 1998 to 2004 vancomycin‐resistant enterococci increased in Europe to 4.1 per cent, and in North America to 6.2 per cent (<a href="./references#CD008056-bbs2-0036" title="FritscheTR , SaderHS , JonesRN . Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999‐2004). Diagnostic Microbiology and Infectious Disease2007;58(1):19‐26. ">Fritsche 2007</a>) </p> <p>The resistance of Gram‐positive bacteria to linezolid has not been noted to the same extent. Linezolid‐resistant <i>Staphylococcus aureus</i> was first isolated in 2001 (<a href="./references#CD008056-bbs2-0055" title="TsiodrasS , GoldHS , SakoulasG , EliopoulosGM , WennerstenC , VenkataramanL , et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet2001;358(9277):207‐8. ">Tsiodras 2001</a>). The seventh year of the Zyvox Annual Appraisal of Potency and Spectrum Program (2008) monitored the in vitro activities of linezolid and comparator agents tested against Gram‐positive pathogens in Latin America, Europe, Canada, and the Asia‐Pacific region. Overall resistance to linezolid in 23 countries was only 0.13 per cent across all monitored Gram‐positive pathogens. Oxazolidinone‐resistant strains continued to be identified in several nations (Brazil, China, France, Germany, Italy, and Sweden) and among three prevalent pathogen groups (<i>S aureus</i>, coagulase‐negative staphylococci, and enterococci) (<a href="./references#CD008056-bbs2-0042" title="JonesRN , RossJE , BellJM , UtsukiU , FumiakiI , KobayashiI , et al. Zyvox(R) Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagnostic microbiology and infectious disease2009;65(4):404‐13. ">Jones 2009</a>). </p> </section> <section id="CD008056-sec-0028"> <h4 class="title">Adverse reactions</h4> <p>The common adverse reactions indicated for vancomycin are nephrotoxicity (damage to kidneys) and ototoxicity (damage to ears) (<a href="./references#CD008056-bbs2-0035" title="FinchRG , EliopoulosGM . Safety and efficacy of glycopeptide antibiotics. Journal of Antimicrobial Chemotherapy2005;55(Suppl 2):ii5‐ii13. ">Finch 2005</a>). These adverse reactions were both side‐effects of early, impure versions of vancomycin (<a href="./references#CD008056-bbs2-0046" title="LevineDP . Vancomycin: a history. Clinical Infectious Diseases2006;42(Supplement 1):S5. ">Levine 2006</a>). Later trials, that used purer forms of vancomycin, found that, while renal toxicity (kidney damage) is an infrequent adverse effect, it is accentuated by the presence of aminoglycosides (<a href="./references#CD008056-bbs2-0035" title="FinchRG , EliopoulosGM . Safety and efficacy of glycopeptide antibiotics. Journal of Antimicrobial Chemotherapy2005;55(Suppl 2):ii5‐ii13. ">Finch 2005</a>). Erythroderma (red man syndrome) may also occur. This syndrome is an allergic reaction characterised by the flushing of the upper body, with itching due to histamine release (<a href="./references#CD008056-bbs2-0053" title="SivagnanamS , DeleuD . Red man syndrome. Critical Care2003;7(2):119‐20. ">Sivagnanam 2003</a>). </p> <p>When used for short periods, linezolid is a relatively safe drug. Long‐term use of linezolid has been associated with bone marrow suppression, which is characterised particularly by thrombocytopenia (low blood platelet count). Thrombocytopenia appears to be the only adverse effect that occurs significantly more frequently with linezolid than with glycopeptides or beta‐lactams (<a href="./references#CD008056-bbs2-0033" title="FalagasME , SiemposII , VardakasKZ . Linezolid versus glycopeptide or beta‐lactam for treatment of Gram‐positive bacterial infections: meta‐analysis of randomised controlled trials. Lancet Infectious Diseases2008;8(1):53‐66. ">Falagas 2008</a>). </p> </section> </section> <section id="CD008056-sec-0029"> <h3 class="title" id="CD008056-sec-0029">Why it is important to do this review</h3> <p>Several studies have compared linezolid with vancomycin; the outcomes were inconsistent. Other reviews have reported that linezolid is more effective than vancomycin in the treatment of SSTIs caused by Gram‐positive bacteria or MRSA (<a href="./references#CD008056-bbs2-0023" title="BeibeiL , YunC , MengliC , NanB , XuhongY , RuiW . Linezolid versus vancomycin for the treatment of Gram‐positive bacterial infections: meta‐analysis of randomised controlled trials. International Journal of Antimicrobial Agents2010;35(1):3‐12. ">Beibei 2010</a>; <a href="./references#CD008056-bbs2-0024" title="BounthavongM , HsuDI . Efficacy and safety of linezolid in methicillin‐resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): A meta‐analysis. Current Medical Research and Opinion2010;26(2):407‐21. ">Bounthavong 2010</a>; <a href="./references#CD008056-bbs2-0033" title="FalagasME , SiemposII , VardakasKZ . Linezolid versus glycopeptide or beta‐lactam for treatment of Gram‐positive bacterial infections: meta‐analysis of randomised controlled trials. Lancet Infectious Diseases2008;8(1):53‐66. ">Falagas 2008</a>). The outcome from another systematic review (<a href="./references#CD008056-bbs2-0028" title="DoddsTJ , HawkeCI . Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta‐analysis). ANZ Journal of Surgery2009;79(9):629‐35. ">Dodds 2009</a>), however, showed that there is no statistically significant difference between linezolid with vancomycin. It disagreed with the conclusions of the other three reviews. Until now, there has been no Cochrane systematic review to summarise the evidence for the beneficial and adverse effects of linezolid compared with vancomycin in people with SSTIs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008056-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008056-sec-0030"></div> <p>To compare the effects of linezolid and vancomycin for treating skin and soft tissue infections. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008056-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008056-sec-0031"></div> <section id="CD008056-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008056-sec-0033"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled trials (RCTs) that compared linezolid with vancomycin in the treatment of skin and soft tissue infections. </p> </section> <section id="CD008056-sec-0034"> <h4 class="title">Types of participants</h4> <p>We included people of any age or gender presenting with skin and soft tissue infections (e.g. cellulitis, erysipelas, furuncles, simple abscesses, wound infections, and deeper infections such as necrotising fasciitis, myositis (inflammation of muscles), and gas gangrene). </p> </section> <section id="CD008056-sec-0035"> <h4 class="title">Types of interventions</h4> <p>Any dose of linezolid or vancomycin, by any route.</p> <p>We intended to present comparisons as follows:<br/> 1. Linezolid compared with vancomycin alone.<br/> 2. Linezolid plus co‐interventions compared with vancomycin plus co‐interventions. </p> <p>Co‐interventions might include other antibiotics for use against Gram‐negative bacteria, or other routine medications and surgical interventions, as long as participants in the different trial arms had equal access to such co‐interventions. </p> </section> <section id="CD008056-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD008056-sec-0037"> <h5 class="title">Primary outcomes</h5> <p>1. Clinical cure (resolution of symptoms and signs) and microbiological cure (eradication of bacteria on wound culture). </p> <p>Proportion of patients or infections healed. We defined healing as either the resolution of all clinical signs and symptoms of infection as assessed by laboratory test or defined by trialists, or microbiological cure (i.e. eradication of MRSA on wound culture). </p> <p>2. SSTI‐related and treatment‐related mortality.</p> </section> <section id="CD008056-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008056-list-0002"> <li> <p>Adverse events.</p> </li> <li> <p>Duration of hospital stay.</p> </li> <li> <p>Duration of treatment.</p> </li> <li> <p>Costs.</p> </li> </ol> </p> </section> </section> </section> <section id="CD008056-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008056-sec-0040"> <h4 class="title">Electronic searches</h4> <p>For this first update of this review we searched the following electronic databases to find reports of relevant RCTs: </p> <p> <ul id="CD008056-list-0003"> <li> <p>The Cochrane Wounds Group Specialised Register (searched 24 March 2015);</p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2015, Issue 2); </p> </li> <li> <p>Ovid MEDLINE (1950 to March Week 4 2015);</p> </li> <li> <p>Ovid MEDLINE (In‐Process &amp; Other Non‐Indexed Citations, March 23 2015);</p> </li> <li> <p>Ovid EMBASE (1980 to March 23 2015);</p> </li> <li> <p>EBSCO CINAHL (1982 to March 24 2012).</p> </li> </ul> </p> <p>The following search strategy was used in CENTRAL and modified appropriately for other databases:<br/> #1 MeSH descriptor Oxazolidinones explode all trees<br/> #2 MeSH descriptor Oxazolone explode all trees<br/> #3 (linezolid* or oxazolone*):ti,ab,kw<br/> #4 MeSH descriptor Glycopeptides explode all trees<br/> #5 (vancomycin* or glycopeptide*):ti,ab,kw<br/> #6 (#1 OR #2 OR #3 OR #4 OR #5)<br/> #7 MeSH descriptor Soft Tissue Infections explode all trees<br/> #8 MeSH descriptor Staphylococcal Skin Infections explode all trees<br/> #9 MeSH descriptor Cellulitis explode all trees<br/> #10 MeSH descriptor Erysipelas explode all trees<br/> #11 MeSH descriptor Furunculosis explode all trees<br/> #12 MeSH descriptor Abscess explode all trees<br/> #13 MeSH descriptor Wound Infection explode all trees<br/> #14 MeSH descriptor Fasciitis, Necrotizing explode all trees<br/> #15 MeSH descriptor Myositis explode all trees<br/> #16 MeSH descriptor Gas Gangrene explode all trees<br/> #17 (soft NEXT tissue NEXT infection* or skin NEXT infection*):ti,ab,kw<br/> #18 (cellulitis or erysipelas or furuncul* or abscess* or absess* or "necrotizing fasciitis" or myositis or "gas gangrene"):ti,ab,kw<br/> #19 (wound* NEAR/2 infect*):ti,ab,kw<br/> #20 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR<br/> #17 OR #18 OR #19)<br/> #21 (#6 AND #20) </p> <p>The search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in <a href="./appendices#CD008056-sec-0113">Appendix 2</a>. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity‐ and precision‐maximizing version (2008 revision) (<a href="./references#CD008056-bbs2-0045" title="LefebvreC , ManheimerE , GlanvilleJ , on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). The Ovid EMBASE and EBSCO CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="./references#CD008056-bbs2-0052" title="Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed 27 May 2008). ">SIGN 2008</a>). There were no restrictions with respect to language, date of publication or study setting. </p> </section> <section id="CD008056-sec-0041"> <h4 class="title">Searching other resources</h4> <p>We also contacted Pharmacia, Pfizer Pharmaceuticals in China for details of unpublished and ongoing trials. We scrutinised citations within all identified trials and major review articles to identify any additional trials. </p> </section> </section> <section id="CD008056-sec-0042"> <h3 class="title" id="CD008056-sec-0042">Data collection and analysis</h3> <section id="CD008056-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Two review authors (YJ and YM) independently scanned the title, abstract and keywords of every record retrieved to determine which studies required further assessment. Full articles were retrieved when the information given in the titles, abstracts and keywords suggested the possibility that: </p> <p> <ol id="CD008056-list-0004"> <li> <p>The study compared linezolid and vancomycin (with or without co‐interventions).</p> </li> <li> <p>The study had a prospective design.</p> </li> </ol> </p> <p>If, after scanning the titles and abstracts, there was any doubt regarding these criteria, we retrieved the full article for clarification. We resolved disagreement by discussion with a third review author (BD), where necessary. </p> </section> <section id="CD008056-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (YJ and YM) independently extracted data using a standard data extraction form specifically adapted for this review. The data extraction form included the following details: </p> <p> <ol id="CD008056-list-0005"> <li> <p><b>General information:</b> whether the paper was published or unpublished, title, authors, country of study, contact address, year of study, language of publication, year of publication, sponsor or funding organisation, setting. </p> </li> <li> <p><b>Methodological details:</b> including criteria for risk of bias assessment (see below). </p> </li> <li> <p><b>Intervention:</b> descriptions of dose, route, and timing of linezolid and vancomycin, with descriptions of dose, route, and timing of co‐medication(s). </p> </li> <li> <p><b>Participants:</b> inclusion and exclusion criteria, total number recruited and numbers in comparison groups, sex, age, baseline characteristics, withdrawals and losses to follow‐up with reasons and descriptions, subgroups. </p> </li> <li> <p><b>Outcomes:</b> clinical cure, microbiological cure, SSTI‐related and treatment‐related mortality, adverse events, duration of treatment, duration of hospitalisation and costs. </p> </li> </ol> </p> <p>If information regarding data was unclear, we attempted to contact the authors of the original study reports to provide further details. When more than one publication related to the same study, we extracted data from all relevant publications, but did not duplicate the data. </p> </section> <section id="CD008056-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (YJ andYM) independently assessed each included study using the Cochrane Collaboration tool for assessing risk of bias (<a href="./references#CD008056-bbs2-0040" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). This tool addresses six specific domains, namely sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other issues (e.g. baseline imbalances) (see <a href="./appendices#CD008056-sec-0114">Appendix 3</a> for details of criteria on which the judgements were based). Blinding and completeness of reporting of outcome data were assessed for each outcome separately. We completed a risk of bias table for each eligible study. We discussed any disagreements amongst all review authors to achieve a consensus. </p> <p>We presented the assessment of risk of bias using a 'risk of bias summary figure', which presents all of the judgments in a cross‐tabulation of study by entry. This display of internal validity indicates the weight the reader may give the results of each study. </p> </section> <section id="CD008056-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <section id="CD008056-sec-0047"> <h5 class="title">Dichotomous data</h5> <p>We presented dichotomous outcomes (e.g. clinical cure, microbiological cure, adverse events, mortality) as risk ratios (RR) with corresponding 95% confidence intervals (CI). For statistically significant effects (primary outcomes), we calculated number the needed to treat (NNT) from the risk difference (RD). </p> </section> <section id="CD008056-sec-0048"> <h5 class="title">Continuous data</h5> <p>We presented continuous data (e.g. duration of hospitalisation, duration of treatment, and costs) as mean differences (MD) with corresponding 95% CI. </p> </section> </section> <section id="CD008056-sec-0049"> <h4 class="title">Unit of analysis issues</h4> <p>Comparisons that randomise or allocate clusters (e.g. clinics) but do not account for clustering during analysis have potential unit of analysis errors resulting in artificially low P values and over‐narrow confidence intervals. We decided to attempt to re‐analyse studies with potential unit of analysis errors by calculating effective sample sizes, where possible (<a href="./references#CD008056-bbs2-0041" title="HigginsJPT , GreenS (editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). If a comparison was re‐analysed, then the P value was to be quoted and annotated as "re‐analysed". If this was not possible, we would have reported only the point estimate (<a href="./references#CD008056-bbs2-0029" title="DonnerA , PiaggioG , VillarJ . Statistical methods for the meta analysis of cluster randomization trials. Statistical Methods in Medical Research2001;10(5):325‐38. ">Donner 2001</a>). If trials included multiple intervention groups receiving a complex intervention as defined above, we would have split the shared control group into two or more groups with smaller sample sizes, depending on the number of interventions studied, and included two or more comparisons (<a href="./references#CD008056-bbs2-0041" title="HigginsJPT , GreenS (editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> </section> <section id="CD008056-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>When data were missing from the trial reports, we attempted to contact the trial authors to request these values. If this was not successful, we conducted intention‐to‐treat (ITT) analysis for all dichotomous outcomes (e.g. clinical cure, microbiological cure, adverse events, mortality). We analysed data on an endpoint basis for continuous outcomes (e.g. duration of hospital stay, duration of treatment, and costs), including only those participants for whom a final data point measurement was obtained (available case analysis). If the standard deviation (SD) was missing, and when the standard error (SE) was available, we imputed the SD from the SE using the formula SD = SE x N<sup>‐2</sup> (<a href="./references#CD008056-bbs2-0041" title="HigginsJPT , GreenS (editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> </section> <section id="CD008056-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>Population, methodology, intervention and outcome measures for each study were assessed for clinical heterogeneity to see if pooling of results was feasible. Assessment for heterogeneity was carried out using the chi‐squared test, with significance set at P value less than 0.1. In addition I<sup>2</sup> was used to estimate the total variation due to heterogeneity across studies (<a href="./references#CD008056-bbs2-0039" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). Values of I<sup>2</sup> less than 25 per cent were regarded as representing low heterogeneity, and we would then use a fixed‐effect model for meta‐analysis. Values of I<sup>2</sup> between 25 and 75 per cent were considered to represent moderate levels of heterogeneity, and we then used a random‐effects model. Values of I<sup>2</sup> higher than 75 per cent indicated high levels of heterogeneity, in which case we did not undertake meta‐analysis. </p> </section> <section id="CD008056-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>If enough studies were identified, funnel plot analysis would have been performed to check for publication bias. </p> </section> <section id="CD008056-sec-0053"> <h4 class="title">Data synthesis</h4> <p>We pooled results following assessment for statistical heterogeneity as described above. Statistical analysis was performed in accordance with the guidelines for statistical analysis in the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD008056-bbs2-0026" title="DeeksJJ , HigginsJPT , AltmanDG , on behalf of theCochrane Statistical Methods Group and the CochraneBias Methods Group (Editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). We conducted a narrative review of eligible studies if there was only one trial or the I<sup>2</sup> statistic was above 75%. A fixed‐effect method would be used where there were too few studies (less than three) to inform the distribution of heterogeneity. </p> </section> <section id="CD008056-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>To assess whether the treatment effect is modified by clinical and demographic variables, we undertook subgroup analyses as follows: </p> <p> <ol id="CD008056-list-0006"> <li> <p>Children (younger than 18 years) and adults (18 years or older).</p> </li> <li> <p>Uncomplicated SSTIs and complicated SSTIs.</p> </li> <li> <p>MRSA subset<b><i>.</i> </b> </p> </li> </ol> </p> </section> <section id="CD008056-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>If a sufficient number of trials were found, sensitivity analysis would be done to assess the robustness of the results as follows: </p> <p> <ol id="CD008056-list-0007"> <li> <p>Exclusion of studies with inadequate concealment of allocation.</p> </li> <li> <p>Exclusion of studies in which outcome evaluation was not blinded.</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008056-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008056-sec-0056"></div> <section id="CD008056-sec-0057"> <h3 class="title">Description of studies</h3> <p>See the "<a href="./references#CD008056-sec-0148" title="">Characteristics of included studies</a>" and "<a href="./references#CD008056-sec-0149" title="">Characteristics of excluded studies</a>" tables. </p> <section id="CD008056-sec-0058"> <h4 class="title">Results of the search</h4> <p>In total, we retrieved 670 articles through searching electronic databases; 11 articles were excluded because they were duplicates, and 659 were excluded after reading the abstracts and applying our inclusion criteria. The full text of the remaining 31 articles was reviewed, and 18 met the inclusion criteria for the review. Of these, thirteen articles were multiple publications, in which nine articles relate to four trials (<a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). Other five papers (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>;<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>) were not multiple publications and referred to one trial each. Finally nine RCTs were included in the review (<a href="#CD008056-fig-0001">Figure 1</a>). No new trials were identified for this first update. </p> <div class="figure" id="CD008056-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008056-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008056-sec-0059"> <h4 class="title">Included studies</h4> <p>Nine RCTs were included in the review (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). Four of these nine RCTs evaluated SSTIs as the only type of infection (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>); four evaluated mixed infections and included types of infection other than SSTIs, such as bacteraemia of unknown source, pneumonia, and urinary tract infections (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>); and one evaluated central venous, pulmonary artery, or arterial catheter‐related infection with a subset of SSTIs (<a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>). </p> <section id="CD008056-sec-0060"> <h5 class="title">Characteristics of studies</h5> <p>All RCTs were parallel‐group studies: two trials were randomised in a 2:1 ratio (<a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>); one was a single‐centre RCT located in the USA (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>), another was a multicentre RCT located in Japan (<a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>); and a third was a multicentre RCT located in China (<a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>). The remaining six RCTs were multinational studies (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). The duration of follow‐up ranged from 28 to 42 days. </p> </section> <section id="CD008056-sec-0061"> <h5 class="title">Characteristics of patients</h5> <p>A total of 4496 participants were randomised, 3114 of whom had SSTIs. The subgroup data for SSTIs were obtained from trial reports; all were complicated SSTIs. Four RCTs reported the types of SSTIs (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>): abscess and infected skin ulcer was the most common infection (39.7%), followed by cellulitis (35.6%) and surgical wound infection (24.7%). Five trials enrolled people with MRSA infections (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>), while four trials enrolled people with Gram‐positive bacterial infection (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). </p> <p>One RCT included children younger than 12 years old, with a mean age of 3.25 years (<a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). Five RCTs included adults (aged 18 years or over) with a mean age of 59.7 years (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>). The remaining three RCTs included mixed populations over the age of 13 years, with a mean age of 54.4 years (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>). </p> <p>All RCTs included both males and females. A larger proportion of males was recruited, and they constituted 58.9% of all randomised patients. Only one RCT recruited more females than males, at 67% (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>). </p> </section> <section id="CD008056-sec-0062"> <h5 class="title">Study treatment details</h5> <p>The doses of each drug were similar in all trials. In the RCTs with participants 13 years old or older, 600 mg linezolid was given as either an intravenous injection (IV) or orally every 12 hours whilst 1000 mg vancomycin was given IV every 12 hours except one RCT(<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>) in which patients were randomised to receive oral or intravenous linezolid 600 mg every 12 hours, or intravenous vancomycin 15 mg/kg mg every 12 hours with dose adjustment as necessary, based on trough levels and creatinine clearance. The route of linezolid administration was IV in two RCTs (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>); IV followed by oral administration in six RCTs (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>); and oral in only one RCT (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>). One RCT that enrolled participants under the age of 12 years (<a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>), gave participants 10 mg/kg IV linezolid every eight hours or 10 to 15 mg/kg vancomycin every six to 24 hours according to age‐dosing guidelines. People with concomitant presumed Gram‐negative or mixed infections were treated with appropriate regimens, mainly aztreonam and aminoglycoside. The two groups had equal access to such co‐interventions. </p> </section> </section> <section id="CD008056-sec-0063"> <h4 class="title">Excluded studies</h4> <p>Eight studies were excluded after assessment of the full‐text. Reasons for exclusion were: </p> <p> <ul id="CD008056-list-0008"> <li> <p>Not a RCT(<a href="./references#CD008056-bbs2-0015" title="JosephWS . Commentary on Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. Foot and Ankle Quarterly‐‐The Seminar Journal2007;19(1):26‐8. ">Joseph 2007</a>; <a href="./references#CD008056-bbs2-0010" title="BalAM , GarauJ , GouldIM , LiaoCH , MazzeiT , NimmoGR , et al. Vancomycin in the treatment of meticillin‐resistant Staphylococcus aureus (MRSA) infection: End of an era?. Journal of global antimicrobial resistance2013; Vol. 1, issue 1:23‐30. ">Bal 2013</a> ) </p> </li> <li> <p>Were cost‐effectiveness analysis (<a href="./references#CD008056-bbs2-0012" title="BounthavongM , HsuDI , OkamotoMP . Cost‐effectiveness analysis of linezolid vs. vancomycin in treating methicillin‐resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. International Journal of Clinical Practice2009;63(3):376‐86. ">Bounthavong 2009</a>; <a href="./references#CD008056-bbs2-0013" title="HauT . Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. European Journal of Clinical Microbiology and Infectious Diseases2002;21(7):491‐8. ">Hau 2002</a>; <a href="./references#CD008056-bbs2-0016" title="KalilAC , PuumalaS , StonerJ . Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin‐resistant Staphylococcus aureus? comment. Antimicrobial Agents and Chemotherapy2006;50(5):1910. ">Kalil 2006</a>; <a href="./references#CD008056-bbs2-0017" title="LipskyBA , ItaniKM , WeigeltJA , JosephW , PaapCM , ReismanA , et al. The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin‐resistant Staphylococcus aureus: results from three randomized controlled trials. International Journal of Infectious Diseases2011;15(2):e140‐6. ">Lipsky 2011</a>; <a href="./references#CD008056-bbs2-0022" title="SchurmannD , SorensenSV , DeCockE , DuttaguptaS , ReschA . Cost‐effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft‐tissue infections in Germany. European Journal of Health Economics2009;10(1):65‐79. ">Schurmann 2009</a>; <a href="./references#CD008056-bbs2-0014" title="JanisJE , HatefDA , ReeceEM , WongC . Does empiric antibiotic therapy change hand infection outcomes? Cost analysis of a randomized prospective trial in a county hospital. Plastic and reconstructive surgery2014; Vol. 133, issue e4511‐8. ">Janis 2014</a>) </p> </li> <li> <p>Were a comment (<a href="./references#CD008056-bbs2-0016" title="KalilAC , PuumalaS , StonerJ . Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin‐resistant Staphylococcus aureus? comment. Antimicrobial Agents and Chemotherapy2006;50(5):1910. ">Kalil 2006</a>) or a review (<a href="./references#CD008056-bbs2-0018" title="McKinnonPS , CarterCT , GirasePG , LiuLZ , CarmeliY . Health economics. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Managed Care Interface2007;20(1):23‐34. ">McKinnon 2007</a>) </p> </li> <li> <p>Were health economics analysis (<a href="./references#CD008056-bbs2-0019" title="PatanwalaAE , ErstadBL , NixDE . Cost‐effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Current Medical Research and Opinion2007;23(1):185‐93. ">Patanwala 2007</a>;) </p> </li> <li> <p>Were post‐hoc pooled data analysis (<a href="./references#CD008056-bbs2-0021" title="PuzniakLA , CapitanoB , BiswasP , LodiseTP . Impact of patient characteristics and infection type on clinical outcomes of patients who received linezolid or vancomycin for complicated skin and skin structure infections caused by methicillin‐resistant Staphylococcus aureus: A pooled data analysis. Diagnostic microbiology and infectious disease2014; Vol. 78, issue 3:295‐301. ">Puzniak 2014</a>; <a href="./references#CD008056-bbs2-0020" title="PuzniakLA , MorrowLE , HuangDB , BarretoJ . Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin‐resistant staphylococcus aureus. Clinical therapeutics2013; Vol. 35, issue 10:1557‐70. ">Puzniak 2013</a>) </p> </li> <li> <p>Not compare linezolid vs. vancomycin (<a href="./references#CD008056-bbs2-0011" title="BhavnaniSM , HammelJP , WartSA , RubinoCM , ReynoldsDK , ForrestA , et al. Pharmacokinetic‐pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections. Antimicrobial agents and chemotherapy2015; Vol. 59, issue 1:372‐80. ">Bhavnani 2015</a>) </p> </li> </ul> </p> </section> </section> <section id="CD008056-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias assessments are detailed in the Characteristics of included studies table and are represented by <a href="#CD008056-fig-0002">Figure 2</a> and <a href="#CD008056-fig-0003">Figure 3</a>. In general, all trials were at high risk of bias. </p> <div class="figure" id="CD008056-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008056-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008056-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008056-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008056-sec-0065"> <h4 class="title">Allocation</h4> <section id="CD008056-sec-0066"> <h5 class="title">Sequence generation</h5> <p>Sequence generation was unclear in all included studies.</p> </section> <section id="CD008056-sec-0067"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was unclear in two RCTs (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>). The treatment allocation was not concealed in the remaining seven studies (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). </p> <p>Overall there was high risk of selection bias.</p> </section> </section> <section id="CD008056-sec-0068"> <h4 class="title">Blinding</h4> <section id="CD008056-sec-0069"> <h5 class="title">Participants</h5> <p>The participants were blinded in <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a> for all reported outcomes. <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a> only reported that the study was "double‐blind", but did not report details about who was blinded. The other seven RCTs were not blinded (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). </p> </section> <section id="CD008056-sec-0070"> <h5 class="title">Care givers</h5> <p>The care givers were blinded in <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a> for all reported outcomes. <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a> only reported that the study was "double‐blind", but did not report details about who was blinded. </p> </section> <section id="CD008056-sec-0071"> <h5 class="title">Outcomes assessor</h5> <p>Two RCTs did not report whether outcome assessors were blinded (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>). The outcome assessors in the other seven RCTs were not blinded (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). </p> <p>Overall, the only two trials that reported being "double‐blind' were small, and contributed to two primary analyses. Most of the trials did not undertake blinding, and so are at high risk of performance and detection bias. </p> </section> </section> <section id="CD008056-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>Two RCTs (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>) did not undertake ITT analyses. Seven RCTs (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>) reported that an ITT analysis was performed. After looking at the full text of the potential seven trials and comparing the data reported at the beginning of randomisation with the data included in the analysis, however, we found that there were discrepancies between baseline data and final analysis which indicated that ITT had not been performed. So we assumed that none of the included trials undertook ITT analyses. Clinical cure and microbiological cure were reported by all studies, other outcomes were reported by some of the trials. We contact the authors requesting these data, but, to date, have received no reply. </p> <section id="CD008056-sec-0073"> <h5 class="title">Clinical and microbiological cure</h5> <p>All RCTs reported clinical and microbiological cure. Two trials, in which incomplete outcome data were adequately addressed, were judged to be at low risk of bias (<a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>). Another two studies reported dropouts only for MRSA infections, but it was not clear how many dropouts were from the SSTIs subset, so we judged the trials to be at unclear risk of bias (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>). The remaining five RCTs did not report reasons or the numbers of dropouts, and were judged to be at high risk of bias. </p> </section> <section id="CD008056-sec-0074"> <h5 class="title">SSTI‐related and treatment‐related mortality</h5> <p>No RCT reported SSTI‐related and treatment‐related mortality. Five RCTs reported all‐cause mortality (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). Of these, three trials reported mortality in SSTI patients (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>), while the other two reported mortality in mixed populations (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>). Mortality data relating to the SSTI groups could not be extracted. </p> </section> <section id="CD008056-sec-0075"> <h5 class="title">Adverse events</h5> <p>Three RCTs evaluated drug‐related adverse events in SSTI participants (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>); one RCT did not report adverse events (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>); while the remaining five RCTs reported adverse events of mixed infection types such as bacteraemia, pneumonia, and urinary tract infections (<a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>). We contacted the study authors for data relating to the SSTI subsets, but have not yet received a response. </p> </section> <section id="CD008056-sec-0076"> <h5 class="title">Duration of hospital stay</h5> <p>Four RCTs reported the duration of hospital stay (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>), reported as the mean number of days and P value. </p> </section> <section id="CD008056-sec-0077"> <h5 class="title">Duration of treatment</h5> <p>Seven RCTs reported the duration of treatment (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>), but only two RCTs specifically reported the results for the subsets of SSTI patients (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005)</a>. </p> </section> <section id="CD008056-sec-0078"> <h5 class="title">Costs</h5> <p>Two trials reported the treatment cost (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>), but <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a> reported only the mean cost and did not report the variance (SD). </p> </section> <section id="CD008056-sec-0079"> <h5 class="title">Conclusion</h5> <p>Overall, two of the nine RCTs adequately addressed incomplete outcome data, and had a low dropout rate (<a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>). In addition, although some of the included studies reported that they undertook ITT analyses, this was not confirmed by the data presented and, therefore, we have judged them to be at high risk of attrition bias. </p> </section> </section> <section id="CD008056-sec-0080"> <h4 class="title">Selective reporting</h4> <p>We found the protocol for one RCT (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>); all of the primary and secondary outcomes pre‐specified in the protocol were subsequently reported, and, accordingly, the trial was judged to be at low risk of bias for this domain. We searched, but did not find the protocols for the other included trials, and so the remaining eight RCTs were judged to be at unclear risk of bias. </p> </section> <section id="CD008056-sec-0081"> <h4 class="title">Other potential sources of bias</h4> <p>There were baseline imbalances in two trials: in <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>, participants in the linezolid group were significantly older than those in the vancomycin group (63.9 versus 59.8 years; P value 0.0157), while in <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>, patients in the linezolid group were significantly younger than those in the vancomycin group (66 versus 76 years). These two trials were judged to be at an high risk of bias for this domain. </p> </section> </section> <section id="CD008056-sec-0082"> <h3 class="title" id="CD008056-sec-0082">Effects of interventions</h3> <section id="CD008056-sec-0083"> <h4 class="title">Linezolid compared with vancomycin (nine RCTs)</h4> <section id="CD008056-sec-0084"> <h5 class="title">Primary outcomes  </h5> <section id="CD008056-sec-0085"> <h6 class="title">Clinical cure</h6> <p>Eight RCTs that reported outcomes in adult or mixed populations (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>), and one RCT that reported outcomes in children (<a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>), were included for this outcome. In total, 3114 participants with SSTIs were randomised in nine RCTs. We conducted ITT analysis for all randomised participants. We coded indeterminate outcomes and missing data as "no cure". Pooling of the nine trials demonstrated a statistically significant difference in cure rate of SSTIs in favour of linezolid (RR 1.09, 95% CI 1.03 to 1.16; I<sup>2</sup> = 13%; <a href="./references#CD008056-fig-0004" title="">Analysis 1.1</a>). The NNT was 20. </p> </section> <section id="CD008056-sec-0086"> <h6 class="title">Microbiological cure</h6> <p>The meta‐analysis to evaluate the microbiological cure rate included 2014 SSTI participants from all nine trials with a positive culture at baseline. More SSTIs achieved microbiological cure when treated with linezolid than with vancomycin (RR 1.08, 95% CI 1.01 to 1.16; I<sup>2</sup> = 42%; <a href="./references#CD008056-fig-0007" title="">Analysis 2.1</a>).The NNT was 20. </p> </section> <section id="CD008056-sec-0087"> <h6 class="title">SSTI‐related and treatment‐related mortality</h6> <p>No RCT reported SSTI‐related or treatment‐related mortality. Three RCTs (2352 participants) reported all‐cause mortality of SSTI patients (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>), and found there was no significant difference in all‐cause mortality between linezolid and vancomycin (RR 1.44, 95% CI 0.75 to 2.80; I<sup>2</sup> = 0%; <a href="./references#CD008056-fig-0010" title="">Analysis 3.1</a>). Although two RCTs (1331 participants) reported mortality data in hospitalised, febrile adults with cancer and proven, or suspected, Gram‐positive bacterial infection (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>); and catheter‐related infection (<a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>), the data were mixed, and mortality data due to SSTIs could not be extracted. We contacted the trial authors to obtain separate mortality data for patients with SSTIs, but have not received any response. The remaining four RCTs did not report mortality data. </p> </section> </section> <section id="CD008056-sec-0088"> <h5 class="title">Secondary outcomes  </h5> <section id="CD008056-sec-0089"> <h6 class="title">Adverse events</h6> <p>One trial (726 participants) reported adverse events including events related, or unrelated, to treatment (<a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>). Seven trials (3710 participants) reported data on treatment‐related adverse events (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). One trial (60 participants) did not mention adverse events (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>). </p> <p>Three RCTs evaluated adverse events in SSTI participants and were included in the meta‐analysis (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>), while the other five RCTs reported data on adverse effects for a variety of infection types, such as bacteraemia, pneumonia, and urinary tract infections, so that data relating to SSTIs could not be extracted (<a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>). </p> <p>Fewer people in the linezolid group had red man syndrome (two RCTs, 1172 patients; RR 0.04, 95% CI 0.01 to 0.29; I<sup>2</sup> = 0%; <a href="./references#CD008056-fig-0013" title="">Analysis 4.3</a>), pruritus (three RCTs, 2352 patients; RR 0.36, 95% CI 0.17 to 0.75; I<sup>2</sup> = 1%; <a href="./references#CD008056-fig-0014" title="">Analysis 4.4</a>), and rash (three RCTs, 2352 patients; RR 0.27, 95% CI 0.12 to 0.58; I<sup>2</sup> = 6%; <a href="./references#CD008056-fig-0015" title="">Analysis 4.5</a>), when compared with vancomycin.<br/> More people in the linezolid group had thrombocytopenia (two RCTs, 1300 patients; RR 13.06, 95% CI 1.72 to 99.22; I<sup>2</sup> = 31%; <a href="./references#CD008056-fig-0016" title="">Analysis 4.6</a>), and nausea (two RCTs, 2232 patients; RR 2.45, 95% CI 1.52 to 3.94; I<sup>2</sup> = 0%; <a href="./references#CD008056-fig-0018" title="">Analysis 4.8</a>).<br/> No differences were reported for anaemia (two RCTs,1300 patients; RR 0.73, 95% CI 0.33 to 1.62; I<sup>2</sup> = 0%; <a href="./references#CD008056-fig-0011" title="">Analysis 4.1</a>), diarrhoea (three RCTs, 2352 patients; RR 1.78, 95% CI 0.82 to 3.88; I<sup>2</sup>= 59%; <a href="./references#CD008056-fig-0012" title="">Analysis 4.2</a>), headache (two RCTs,2232 patients; RR 1.23, 95% CI 0.59 to 2.61; I<sup>2</sup>= 59%; <a href="./references#CD008056-fig-0017" title="">Analysis 4.7</a>), or vomiting (two RCTs, 2232 patients; RR 2.20, 95% CI 0.96 to 5.04; I<sup>2</sup> = 0%; <a href="./references#CD008056-fig-0019" title="">Analysis 4.9</a>). </p> </section> <section id="CD008056-sec-0090"> <h6 class="title">Duration of hospital stay</h6> <p>Four RCTs (2522 participants) reported the duration of hospital stay (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>), but reported only the mean days and P value. <a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a> showed that in the linezolid group, the median and mean lengths of stay (LOS) were 5.0 and 7.7 days, respectively, compared with 7.0 and 8.9 days, respectively, in the vancomycin group (P value 0.016). <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a> reported that the median LOS was three days shorter with linezolid (P value 0.003). <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a> reported that LOS was five days shorter for the linezolid group than the vancomycin group (9 versus 14 days, P value 0.052) among patients with SSTI. <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a> found that the mean all cause total LOS was significantly shorter in the linezolid arm (7.4 versus 9.8 days, P value less than 0.0001). </p> </section> <section id="CD008056-sec-0091"> <h6 class="title">Duration of treatment</h6> <p>Seven RCTs (4316 participants) reported the treatment duration (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>), but only two reported results for the subset of SSTI patients (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005)</a>. <a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a> reported only the mean days and P value. The mean duration of intravenous therapy was reported as being significantly shorter in the linezolid group than the vancomycin group (5.3 versus 9.8 days; P value 0.001). For <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>, however, the mean treatment duration was longer for the linezolid group than for the vancomycin group (MD 0.90 days, 95% CI 0.32 to 1.48; <a href="./references#CD008056-fig-0020" title="">Analysis 5.1</a>). </p> </section> <section id="CD008056-sec-0092"> <h6 class="title">Costs</h6> <p>Two RCTs (1240 participants) reported the treatment cost (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>), but <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a> did not report the SD or SE.The daily cost of outpatient therapy was USD 97 less with oral linezolid than with intravenous vancomycin (USD 103 versus USD 200, P value less than 0.001). Medication charges per day for inpatient linezolid treatment were USD 117 more than those for inpatient vancomycin (USD 277 versus USD 160, P value 0.069). However, the median length of hospital stay was three days shorter with linezolid (P value 0.003). Thus, with linezolid treatment, an average of USD 6438 in total hospital charges per patient was avoided (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>). <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a> found that mean cost (plus or minus SD) for treatIing with linezolid was less than for vancomycin; that is, USD 4865 plus or minus USD 4367 compared with USD 5738 plus or minus USD 5190, respectively (P value 0.017). </p> </section> </section> <section id="CD008056-sec-0093"> <h5 class="title">Subgroup analyses</h5> <section id="CD008056-sec-0094"> <h6 class="title">1. Children (under 18 years) and adults (18 years or over)</h6> <p>There was only one study (120 participants) in children (<a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>), though five RCTs (2402 participants) included adults (18 years or over) with SSTI (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>). The remaining three RCTs (592 participants) included mixed populations (13 years and over) with SSTI (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>). In children, there was no statistically significant difference for either clinical cure (RR 1.14; 95% CI 0.91 to 1.44) or microbiological cure (RR 1.08; 95% CI 0.90 to 1.31). In adults (18 years and over), there was a statistically significant difference in favour of linezolid for both clinical cure (RR 1.16; 95% CI 1.02 to 1.32; I<sup>2</sup> = 42%; <a href="./references#CD008056-fig-0005" title="">Analysis 1.2</a>) and microbiological cure (RR 1.17; 95% CI 1.02 to 1.34; I<sup>2</sup> = 61%; <a href="./references#CD008056-fig-0008" title="">Analysis 2.2</a>). There were insufficient data to undertake subgroup analyses for other outcomes. </p> </section> <section id="CD008056-sec-0095"> <h6 class="title">2. Uncomplicated SSTIs and complicated SSTIs</h6> <p>No trial reported uncomplicated SSTIs. This meant that there were insufficient data to permit this subgroup analysis. </p> </section> <section id="CD008056-sec-0096"> <h6 class="title">3. MRSA subset</h6> <p>Five RCTs (2570 participants) enrolled people with MRSA infections (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>). One RCT enrolled people with Gram‐positive bacterial infection, but reported data of MRSA as a subset (89 participants) (<a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>). Thus, six RCTs reported the clinical and microbiological cure rate of MRSA infections. Clinical cure was evaluated in the people who were suspected or proven to have MRSA infections (2659 participants), while microbiological cure rate was evaluated for the people who had a positive MRSA culture at baseline (1289 participants). The results showed that linezolid achieved both a significantly better clinical cure rate (RR 1.09, 95% CI 1.03 to 1.17; I<sup>2</sup> = 0%; <a href="./references#CD008056-fig-0006" title="">Analysis 1.3</a>), and microbiological cure rate (RR 1.17, 95% CI 1.04 to 1.32; I<sup>2</sup> = 46%; <a href="./references#CD008056-fig-0009" title="">Analysis 2.3</a>), than vancomycin. There were insufficient data to do subgroup analyses for other outcomes. </p> </section> </section> <section id="CD008056-sec-0097"> <h5 class="title">Sensitivity analysis</h5> <section id="CD008056-sec-0098"> <h6 class="title">1. Exclusion of studies with inadequate concealment of allocation</h6> <p>Allocation concealment was unclear in all included RCTs and, therefore, this analysis was not undertaken. </p> </section> <section id="CD008056-sec-0099"> <h6 class="title">2. Exclusion of studies in which outcome evaluation was not blinded</h6> <p>Only two of the nine included trials had a blinded design (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>). After removal of the studies in which outcome evaluation was not blinded, there was no difference in treatment success for clinical cure for patients (RR 1.22, 95% CI 0.97 to 1.53), or for microbiological cure for patients (RR 1.08, 95% CI 0.85 to 1.38). There was no blinding for any other outcome for the RCTs, so there were insufficient data to perform the planned sensitivity analyses. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008056-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008056-sec-0100"></div> <section id="CD008056-sec-0101"> <h3 class="title" id="CD008056-sec-0101">Summary of main results</h3> <p>This review evaluated the effects and safety of linezolid compared with vancomycin for the treatment of people with skin and soft tissue infections (SSTIs). Of the 26 studies initially identified, nine (with 18 citations) were included in the review. </p> <p>In summary, the included RCTs were of poor methodological quality, with high risk of bias, which weakens the confidence that can be placed on the individual and pooled results. The results of our review suggest that linezolid was more effective than vancomycin for treatment of SSTIs. Linezolid treatment was associated with a better clinical cure rate (RR 1.09, 95% CI 1.03 to 1.16), and better microbiological cure rate (RR 1.08, 95% CI 1.01 to 1.16). There was no significant difference in mortality between linezolid and vancomycin (RR 1.44, 95% CI 0.75 to 2.80). The linezolid group had a lower incidence of red man syndrome (RR 0.04, 95% CI 0.01 to 0.29), pruritus (RR 0.36, 95% CI 0.17 to 0.75), and rash (RR 0.27, 95% CI 0.12 to 0.58) than vancomycin. The linezolid group, however, had a greater incidence of thrombocytopenia (RR 13.06, 95% CI 1.72 to 99.22), and nausea (RR 2.45, 95% CI 1.52 to 3.94). We undertook subgroup analyses in people who had MRSA infections and found that linezolid was more effective than vancomycin in achieving a clinical cure (RR 1.09, 95% CI 1.03 to 1.17) and a microbiological cure (RR 1.17, 95% CI 1.04 to 1.32). We also undertook subgroup analyses in children (under 18 years of age) and adults (18 years and over). In children, there was no statistically significant difference for clinical cure and microbiological cure (one RCT <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). In adults (18 years and over), there was a statistically significant difference in favour of linezolid for both clinical cure (RR 1.16; 95% CI 1.02 to 1.32) and microbiological cure (RR 1.17; 95% CI 1.02 to 1.34).The lengths of stay in hospital were shorter for the linezolid group than the vancomycin group. The daily cost of outpatient therapy was less with oral linezolid than with intravenous vancomycin. Although inpatient treatment with linezolid cost more than inpatient treatment with vancomycin per day, the median length of hospital stay was three days shorter with linezolid. Thus, total hospital charges per patient was less with linezolid treatment than with vancomycin treatment. </p> </section> <section id="CD008056-sec-0102"> <h3 class="title" id="CD008056-sec-0102">Overall completeness and applicability of evidence</h3> <p>The outcomes reported in the trials focused on clinical and microbiological cure. Economics of health, such as duration of hospital stay, treatment duration and cost were reported in only a few RCTs. Four RCTs reported the duration of hospital stay (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>), but they only reported the mean days and P value. Only two RCTs reported results for subsets of SSTI patients (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005)</a>. The duration of intravenous treatment was shorter for patients treated with linezolid in <a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>, however, it was longer in <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>. Two trials reported the treatment cost (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>). </p> <p>No RCT reported SSTI‐related and treatment‐related mortality, and only three reported all‐cause mortality and adverse effects for the subset of SSTI patients (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). Other RCTs reported the outcome for a pooled population of patients with mixed infection types, but, as we know, potential differences in mortality and adverse effects may exist within these different infection types. Unless individual subsets of patients were investigated, this result could not reflect mortality or adverse events specifically for SSTIs. </p> <p>Six of the nine included trials were multinational studies (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0008" title="WilcoxMH , TackKJ , BouzaE , HerrDL , RufBR , LjzermanMM . Complicated skin and skin‐structure infections and catheter‐related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clinical Infectious Diseases2009;48(2):203‐12. ">Wilcox 2009</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>); the remaining three were located in the USA (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>), Japan (<a href="./references#CD008056-bbs2-0003" title="KohnoS , YamaguchiK , AikawaN , SumiyamaY , OdagiriS , AokiN , et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin‐resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy2007;60(6):1361‐9. ">Kohno 2007</a>), and China (<a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>). Participants came from diverse cultural and geographic backgrounds, were of all ages, and both sexes were represented, therefore, this review is representative of different racial and regional groups. </p> </section> <section id="CD008056-sec-0103"> <h3 class="title" id="CD008056-sec-0103">Quality of the evidence</h3> <p>In general, all the trials were of poor methodological quality. Firstly, although all studies stated that randomisation was used, none mentioned the method of randomisation. Treatment allocation was not concealed in seven of the trials and it was unclear whether it had been in the remaining two RCTs. The lack of disclosure of the method of randomisation and the lack of allocation concealment in all included trials is concerning. Treatment effect may be overestimated by 30 to 40 per cent when allocation concealment is absent (<a href="./references#CD008056-bbs2-0050" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>). Secondly, only two of the nine RCTs (with small sample sizes) had a blinded design (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>), and lack of blinding might cause an overestimation of treatment effects.Thirdly, seven of the nine RCTs were either unclear about, or did not report dropout data, and none of them undertook an ITT analysis. The omission or non‐reporting of these items may lead to, or indicate, attrition bias that may contribute to false positive or negative findings. Finally, all the trials were funded by the pharmaceutical company that produces linezolid. It should be noted that, while the pharmaceutical companies need to support research in an ethical manner, pharmaceutical funding may introduce publication bias and, in this case, might overestimate the effects of linezolid. </p> </section> <section id="CD008056-sec-0104"> <h3 class="title" id="CD008056-sec-0104">Potential biases in the review process</h3> <p>1. We could not perform a funnel plot to investigate publication bias in this systematic review due to the small numbers of trials. Thus, one of our concerns is the potential for publication bias. The pharmaceutical company that produces linezolid funded all nine of the included trials in this review, which might mean that positive results are more likely to be reported than negative ones. Previously an association between positive results and publication has been demonstrated (<a href="./references#CD008056-bbs2-0027" title="DickersinK . The existence of publication bias and risk factors for its occurrence. JAMA1990;263(10):1385. ">Dickersin 1990</a>), which may have identified a potential source of bias that, in this case, could have led to an overestimation of the treatment effect. </p> <p>2. All RCTs excluded patients with severe SSTIs, such as necrotising fasciitis, gas gangrene, and infected burns, therefore, the effects of linezolid or vancomycin for such severe infections could not be estimated. </p> <p>3. We undertook subgroup analysis for MRSA‐infected SSTIs. Two potential biases need to be considered: firstly, when a person presents with a SSTI, the identity of the infecting pathogen is usually not known. Whilst, for the outcome of clinical cure, it was suspected that the participants had MRSA‐infected SSTIs, MRSA can only be identified after culture. Secondly, although testing for microbiological eradication may provide definitive confirmation that the MRSA SSTI has been resolved, use of this endpoint is confounded by people who have natural colonisation of MRSA. This may be a potential source of bias, as it could have led to an underestimate of the treatment effect. Hence, clinicians should consider both the clinical and microbiological cure as indicators of treatment response. </p> <p>4. The heterogeneity in this review was somewhat high for five outcomes. Possible reasons for this could include the lack of concealment of allocation, failure to perform an intention‐to‐treat analysis, and underlying patient characteristics such as different types of SSTIs and age. </p> <p>5. After removal of the trials in which outcome assessment was not blinded, there were only two trials (<a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0004" title="LinDF , WuJF , ZhangYY , ZhengJC , MiaoJZ , ZhengLY , et al. A randomized, double‐blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection. Chinese Journal of Infection and Chemotherapy2009;9(1):10‐7. LinDf , ZhangYY , WuJF , WangF , ZhengJC , MiaoJZ , et al. Linezolid for the treatment of infections caused by Gram‐positive pathogens in China. International Journal of Antimicrobial Agents2008;32(3):241‐9. ">Lin 2008</a>). Sensitivity analyses showed no difference in treatment success for clinical or microbiological cure. This may be due to the small sample sizes of the trials included (109 participants). </p> </section> <section id="CD008056-sec-0105"> <h3 class="title" id="CD008056-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>Our results are in agreement with some studies. Worldwide clinical trials with linezolid have demonstrated that linezolid has significantly better clinical and microbiological cure rates than vancomycin in people with pneumonia (<a href="./references#CD008056-bbs2-0043" title="KollefMH , RelloJ , CammarataSK , Croos‐DabreraRV , WunderinkRG . Clinical cure and survival in Gram‐positive ventilator‐associated pneumonia: retrospective analysis of two double‐blind studies comparing linezolid with vancomycin. Intensive Care Medicine2004;30(3):388‐94. ">Kollef 2004</a>; <a href="./references#CD008056-bbs2-0057" title="WunderinkRG , RelloJ , CammarataS , Croos‐DabreraRV , KollefMH . Linezolid vs vancomycin: analysis of two double‐blind studies of patients with methicillin‐resistant Staphylococcus aureus nosocomial pneumonia. Chest2003;124(5):1789‐97. ">Wunderink 2003</a>). There also are some reviews which have favoured linezolid: one meta‐analysis evaluated the clinical and microbiological outcomes of linezolid compared with vancomycin in MRSA complicated SSTIs (<a href="./references#CD008056-bbs2-0024" title="BounthavongM , HsuDI . Efficacy and safety of linezolid in methicillin‐resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): A meta‐analysis. Current Medical Research and Opinion2010;26(2):407‐21. ">Bounthavong 2010</a>): it reported that resolution of infection favoured the use of linezolid over vancomycin (OR 1.41; 95% CI: 1.03 to 1.95), and that microbiological eradication in MRSA patients consistently favoured the use of linezolid (OR 2.90; 95% CI: 1.90 to 4.41). Another meta‐analysis also demonstrated that linezolid was more effective than vancomycin (OR 1.40, 95% CI 1.01 to 1.95) in people with SSTIs (<a href="./references#CD008056-bbs2-0023" title="BeibeiL , YunC , MengliC , NanB , XuhongY , RuiW . Linezolid versus vancomycin for the treatment of Gram‐positive bacterial infections: meta‐analysis of randomised controlled trials. International Journal of Antimicrobial Agents2010;35(1):3‐12. ">Beibei 2010</a>). For adverse effects, both reviews found that people treated with linezolid had higher proportions of thrombocytopenia, and a higher proportion of people treated with vancomycin had renal insufficiency. No difference in mortality was reported between the two antibiotics. Nonetheless, these reviews have limitations: they assessed mortality and adverse effects using mixed data, whilst data due to SSTIs could not be extracted. As we know, the mortality and side effects of SSTIs may not be the same as with other infections. For example, the mortality for bacteraemia is higher than for SSTIs. Secondly, some RCTs we identified and included in this review were not included in the earlier reviews (<a href="./references#CD008056-bbs2-0001" title="ItaniKM , DrydenMS , BhattacharyyaH , KunkelMJ , BaruchAM , WeigeltJA . Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft‐tissue infections proven to be caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2010;199(6):804‐16. ">Itani 2010</a>; <a href="./references#CD008056-bbs2-0002" title="JaksicB , MartinelliG , Perez‐OteyzaJ , HartmanCS , LeonardLB , TackKJ . Efficacy and safety of linezolid compared with vancomycin in a randomized, double‐blind study of febrile neutropenic patients with cancer. Clinical Infectious Diseases2006;42(5):597‐607. ">Jaksic 2006</a>; <a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>). </p> <p>Despite this, our results are inconsistent with some other reviews. One review compared the effects of linezolid with vancomycin for the treatment of MRSA SSTIs in hospital inpatients (<a href="./references#CD008056-bbs2-0028" title="DoddsTJ , HawkeCI . Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta‐analysis). ANZ Journal of Surgery2009;79(9):629‐35. ">Dodds 2009</a>). This review included four trials with a total of 174 participants for clinical outcomes and 439 participants for microbiological outcomes, respectively (<a href="./references#CD008056-bbs2-0005" title="SharpeJN , ShivelyEH , PolkHC . Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA‐complicated, lower‐extremity skin and soft‐tissue infections caused by methicillin‐resistant Staphylococcus aureus. American Journal of Surgery2005;189(4):425‐8. ">Sharpe 2005</a>; <a href="./references#CD008056-bbs2-0006" title="LiJZ , WillkeRJ , RittenhouseBE . Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin‐resistant staphylococci: results from a randomized clinical trial. Surgical Infections2003;4(1):57‐70. LiZ , WillkeRJ , PintoLA , RittenhouseBE , RybakMJ , PleilAM , et al. Comparison of length of hospital stay for patients with known or suspected methicillin‐resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy2001;21(3):263‐74. StevensDL , HerrD , LampirisH , HuntJL , BattsDH , HafkinB . Linezolid versus vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infections. Clinical Infectious Diseases2002;34(11):1481‐90. ">Stevens 2002</a>; <a href="./references#CD008056-bbs2-0007" title="ItaniKM , WeigeltJ , LiJZ , DuttaguptaS . Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin‐resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents2005;26(6):442‐8. McCollumM , SorensenSV , LiuLZ . A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft‐tissue infections caused by suspected or confirmed methicillin‐resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics2007;29(3):469‐77. McKinnonPS , SorensenSV , LiuLZ , ItaniKM . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft‐tissue infections. Annals of pharmacotherapy2006;40(6):1017‐23. WeigeltJ , ItaniK , StevensD , LauW , DrydenM , KnirschC , et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy2005;49(6):2260‐6. WeigeltJ , KaafaraniHM , ItaniKM , SwansonRN . Linezolid eradicates MRSA better than vancomycin from surgical‐site infections. American Journal of Surgery2004;188(6):760‐6. ">Weigelt 2005</a>; <a href="./references#CD008056-bbs2-0009" title="DevilleJG , AdlerS , AzimiPH , JantauschBA , MorfinMR , BeltranS , et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram‐positive infections in neonates. Pediatric Infectious Disease Journal2003;22(9 suppl):S158‐63. KaplanSL , AfghaniB , LopezP , WuE , FleishakerD , Edge‐PadburyB , et al. Linezolid for the treatment of methicillin‐resistant Staphylococcus aureus infections in children. Pediatric Infectious Disease Journal2003;22(9 Suppl):S178‐85. YogevR , PattersonLE , KaplanSL , AdlerS , MorfinMR , MartinA , et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal2003;22(9 SUPPL):S172‐7. ">Yogev 2003</a>). There was no significant effect for clinical outcomes (RR 0.34; 95% CI 0.04 to 2.89) or microbiological outcomes (RR 0.55; 95% CI 0.30 to 1.01). Another review compared linezolid with vancomycin (<a href="./references#CD008056-bbs2-0051" title="ShorrAF , KunkelMJ , KollefM . Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. Journal of Antimicrobial Chemotherapy2005;56(5):923. ">Shorr 2005</a>), and concluded that linezolid was not inferior to vancomycin in patients with secondary <i>S aureus</i> bacteraemia (five RCTs; 144 adults with <i>S aureus</i> bacteraemia). These two reviews were small, which may be a possible cause of these inconsistencies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008056-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008056-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#CD008056-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008056-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#CD008056-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008056-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/full#CD008056-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clinical cure, Outcome 1 All participants." data-id="CD008056-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Clinical cure, Outcome 1 All participants.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clinical cure, Outcome 2 Adults' subgroup (≥ 18 years)." data-id="CD008056-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Clinical cure, Outcome 2 Adults' subgroup (≥ 18 years).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clinical cure, Outcome 3 MRSA subgroup." data-id="CD008056-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Clinical cure, Outcome 3 MRSA subgroup.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Microbiological cure, Outcome 1 All participants." data-id="CD008056-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Microbiological cure, Outcome 1 All participants.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Microbiological cure, Outcome 2 Adults' subgroup (≥ 18 years)." data-id="CD008056-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Microbiological cure, Outcome 2 Adults' subgroup (≥ 18 years).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Microbiological cure, Outcome 3 MRSA subgroup." data-id="CD008056-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Microbiological cure, Outcome 3 MRSA subgroup.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Mortality, Outcome 1 All‐cause mortality during follow‐up." data-id="CD008056-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Mortality, Outcome 1 All‐cause mortality during follow‐up.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 1 Anaemia." data-id="CD008056-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 1 Anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 2 Diarrhoea." data-id="CD008056-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 2 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 3 Red man syndrome." data-id="CD008056-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 3 Red man syndrome.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 4 Pruritus." data-id="CD008056-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 4 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 5 Rash." data-id="CD008056-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 5 Rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 6 Thrombocytopenia." data-id="CD008056-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 6 Thrombocytopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 7 Headache." data-id="CD008056-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 7 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 8 Nausea." data-id="CD008056-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 8 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse events, Outcome 9 Vomiting." data-id="CD008056-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Adverse events, Outcome 9 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008056-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/urn:x-wiley:14651858:media:CD008056:CD008056-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_t/tCD008056-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Duration of treatment, Outcome 1 Duration of treatment (day)." data-id="CD008056-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Duration of treatment, Outcome 1 Duration of treatment (day).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/media/CDSR/CD008056/image_n/nCD008056-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD008056-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Clinical cure</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [1.03, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adults' subgroup (≥ 18 years) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.02, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 MRSA subgroup <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [1.03, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Clinical cure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008056-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Microbiological cure</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [1.01, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adults' subgroup (≥ 18 years) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.02, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 MRSA subgroup <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.04, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Microbiological cure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008056-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Mortality</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.75, 2.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008056-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.33, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.81, 3.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Red man syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.17, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.12, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.06 [1.72, 99.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.59, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [1.52, 3.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.96, 5.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008056-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Duration of treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Duration of treatment (day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.32, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Duration of treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008056.pub3/references#CD008056-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008056.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008056-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008056-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD008056-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pl#CD008056-note-0002">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008056-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008056\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008056\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008056\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008056\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008056\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008056.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008056.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008056.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008056.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008056.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717292818"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008056.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717292821"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008056.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db4626f079365',t:'MTc0MDcxNzI5My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 